Alzheimer's and Aducanumab: The Beta Amyloid Theory's Last Hope
Despite $2.8 billion allocated by the NIH to Alzheimer's research in 2020 alone, results to date have been rocky. Why is this disease that affects millions of people so tough to crack? This episode of CBPartners’ podcast seeks to answer this question as healthcare consultant Jared Wolff, is joined by Sophie Katz, and Anna Du, as they delve into:
- The primary focus of Alzheimer’s research and treatments
- Likelihood assessment of the FDA approving Biogen’s aducanumab
- High value AD targets that should be a future focus
We hope you enjoy the content and thanks for listening!